EGFR and neoplasm: Even though none of these genetic polymorphisms significantly predicted tumor recurrence among these patients, EGFR:rs2227983, VEGF:rs2010963, and EGF:rs2237051 showed borderline significance for disease progression (P = 0.058 for EGFR:rs2227983, P = 0.073 for VEGF:rs2010963, and P = 0.104 for EGF:rs2237051; Table 2).